The grant provides funds to evaluate effectiveness of the company’s proprietary long acting gamma interferon analog for the treatment of ovarian cancer in animal models.
The Small Business Innovation Research program provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs. Companies that successfully meet the goals of the Phase I grant are eligible to apply for an additional $750,000 in phase II grant support to continue their product development efforts.
Bolder BioTechnology uses advanced protein engineering technologies to create human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases.